Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cadence Design Systems Inc (CDNS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Cadence Design Systems IncTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Cadence Design Systems Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Cadence Design Systems Inc trades at $326.35 (market cap $90.20B), while State Street SPDR S&P Biotech ETF trades at $159.82. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Cadence Design Systems Inc nearer its low. Which is the better fit depends on your goals.

CDNSXBI
Market Cap
$90.20B
Sector
TechnologyBroad Market / Factor
52-Week High
$416.39$164.28
52-Week Low
$265.66$86.92
Enterprise Value
$91.41B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cadence Design Systems Inc

Cadence Design Systems (CDNS) trades at $331.91, down 2.16% amid a bearish technical signal, though it remains supported by strong fundamentals. The company reported Q2 2026 earnings that beat estimates, with revenue growth of 24.2% driven by AI demand, and raised its full-year outlook. Analyst consensus is strongly bullish with an average price target of $415.11, representing 25% upside potential from current levels.

The stock offers compelling growth prospects from AI-driven semiconductor design demand, with record backlog of $8.1 billion supporting future revenue visibility. Key risks include high valuation multiples (P/E 65.12) and potential semiconductor cycle volatility. Institutional ownership remains strong with recent position increases by major funds like Amundi.

State Street SPDR S&P Biotech ETF

XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.

Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.

Returns comparison

Trailing returns across standard periods

About Cadence Design Systems Inc

Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.

Read more on CDNS

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI